Navigation Links
Enlight Biosciences Expands to direct up to $52 Million to Transformational Enabling Technologies
Date:1/22/2009

BOSTON, Jan. 22 /PRNewswire/ -- Enlight Biosciences LLC, a Boston-based company conceived in partnership with major pharmaceutical companies and academic luminaries, announced today that Johnson & Johnson has joined the initiative. As a partner, Johnson & Johnson will have the opportunity to invest in the development of strategic technologies that have the potential to fundamentally transform drug discovery and development and to apply these pre-competitive technologies to its therapeutic programs. With the participation of Johnson & Johnson, Enlight and its partners are now poised to direct a combined total of up to $52M toward these advances.

(Logo: http://www.newscom.com/cgi-bin/prnh/20080710/NETH017LOGO )

"The Enlight collaboration will benefit from the expansive scope of science and commercial expertise from Johnson & Johnson, as well as from the company's commitment to an open innovation model of supporting universities and medical centers," states Dr. Frank Douglas, Enlight Board Member, PureTech Ventures Senior Partner and former Chief Scientific Officer and Executive Vice President of Aventis.

Enlight proactively addresses critical unmet industry needs with innovations drawn from academic laboratories, startups, and ideas generated internally by the Enlight team. Enlight is focused on areas that include molecular imaging, biologics, and drug formulation and delivery methods, as well as novel synthesis and production technologies and library screening. Enlight evaluates hundreds of technology opportunities per year, selecting only the top one or two to become actively managed programs.

According to Garry A. Neil, M.D., Corporate Vice President, Johnson & Johnson Corporate Office of Science and Technology, "Participation in this initiative will allow us to work with our consortium peers to identify technology needs and influence future industry standards. Our membership aligns with our interest in early-stage discovery platforms, enables us to review promising technologies according to our specifications prior to full development, and supports our commitment to academic research and entrepreneurship."

Enlight's launch was announced in July 2008 by PureTech Ventures, a venture creation firm translating research from top-tier academic institutions into therapies, along with existing Enlight partners Merck & Co., Inc., Pfizer Inc. and Eli Lilly. Enlight's scientific advisory board is led by Nobel Laureate Dr. H. Robert Horvitz, Koch Professor of Biology at the Massachusetts Institute of Technology and an Investigator of the Howard Hughes Medical Institute.

Johnson & Johnson will collaborate with the Enlight team and the other pharmaceutical partners to guide Enlight's focus areas and strategic directions, prioritize desired technologies and select active programs. Participation in the Enlight venture will enable the research units of the pharmaceutical companies within the Johnson & Johnson Family of Companies to review a large number of innovative technologies, platforms and tools and to shape the types and focus of such promising research through collaboration with the other partner companies. Johnson & Johnson, like the other partners, will have preferential access to technologies developed by new companies it opts to fund.

"Participation in this collaboration will also enable our research units to make pre-competitive knowledge available across the industry," said Roger Pomerantz, M.D., President, Tibotec Research and Development, and Senior Vice President, Global Virology, Johnson & Johnson. "We are excited about this opportunity to contribute to increasing the standard of medical care, particularly in our focus areas of oncology, cardiovascular and inflammation."

About Enlight

Enlight is a Boston-based company established in partnership with major pharmaceutical companies to develop breakthrough innovations that will fundamentally alter drug discovery and development.

Enlight was co-founded by PureTech Ventures and academic luminaries led by Dr. H. Robert Horvitz, Enlight's SAB Chair, Nobel Laureate, Howard Hughes Investigator, and Koch Professor of Biology at MIT; Dr. Sam Gambhir, Professor of Radiology, Chief of the Division of Nuclear Medicine, Stanford; Dr. Rakesh Jain, Cook Professor of Tumor Biology at MGH and Harvard Medical School; and Dr. Raju Kucherlapati, co-founder of Millennium and Abgenix, Cabot Professor of Genetics at Harvard Medical School.

Enlight's team also includes leading drug developers and innovators, such as Dr. Frank Douglas, PureTech Ventures Senior Partner, former Chief Scientific Officer and Executive Vice President of Aventis; and Dr. Bennett Shapiro, PureTech Ventures Senior Partner, former Executive Vice President of Basic Research and Worldwide Licensing at Merck & Co., Inc.

About PureTech Ventures

PureTech Ventures is a Boston-based venture creation firm specializing in translating breakthrough research from top tier academic institutions into therapies that will impact human health. PureTech's Senior Partners include entrepreneurs and leaders from the top echelon of pharma, biotech and academia. www.puretechventures.com


'/>"/>
SOURCE Enlight Biosciences LLC
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Positively Conscious: An Enlightened Look At Life
2. Sangamo BioSciences to Present at the ThinkEquity Partners Growth Conference
3. Akers Biosciences, Inc. ABI or the Company Receipt of Further United States Military Contracts
4. Pressure BioSciences to Present at the Rodman & Renshaw BioFin 9th Annual Healthcare Conference in New York City on November 5th
5. Neurocrine Biosciences to Present at the CIBC World Markets 18th Annual Healthcare Conference
6. Pressure BioSciences, Inc. to Discuss Third Quarter Financial Results and Provide Business Update
7. Monogram Biosciences to Present at The Lazard Capital Markets Fourth Annual Healthcare Conference
8. Anaptys Biosciences Raises Over $33 Million in Series B Financing
9. YM BIOSCIENCES REPORTS FIRST QUARTER 2008 OPERATIONAL AND FINANCIAL RESULTS
10. Pressure BioSciences, Inc. Reports Third Quarter 2007 Financial Results and Provides Business Update
11. Schering-Plough Receives Clearance From U.S. Federal Trade Commission for Planned Acquisition of Organon Biosciences N.V.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/26/2017)... ... 26, 2017 , ... Mediaplanet is proud to announce the launch of its ... will educate readers on how to take care of all aspects of their skin. ... on melanoma. Dancing with the Stars professional, Witney Carson, shares her journey with the ...
(Date:5/26/2017)... ... May 26, 2017 , ... The Radiology Business ... focus on current legislative activity and the latest regulatory concerns impacting RBMA members. ... Sept. 10, and will continue through Monday, Sept. 11, at the Ritz-Carlton, Tysons ...
(Date:5/26/2017)... MN (PRWEB) , ... May 26, 2017 , ... A ... U.S. states with the healthiest seniors are located in the Midwest. With the average ... more and more people are concerned with both the quality and affordability of where ...
(Date:5/26/2017)... ... ... On May 24, the Congressional Budget Office (CBO) projected that the amended ... would result in 23 million Americans losing their health insurance by 2026 as compared ... Affordable Care Act (ACA). , “It is clear from the CBO analysis that ...
(Date:5/26/2017)... ... May 26, 2017 , ... Silver Birch of Hammond, a new assisted ... more than four acres of land at 5620 Sohl Avenue in Hammond, serves older ... building includes 125 studio and one-bedroom apartments. Each of the private apartments at Silver ...
Breaking Medicine News(10 mins):
(Date:5/15/2017)... , May 15, 2017 Enterin Inc., a ... and developing novel compounds to treat Parkinson,s disease (PD), ... study is a Phase 1/2a randomized, controlled, multicenter study involving ... It will enroll 50 patients over a 9-to-12-month period. The ... in 10 patients with PD. Participating sites include ...
(Date:5/10/2017)...  The Corporate Whistleblower Center says, "We are ... clinics to call us anytime at 866-714-6466 if they ... in a substantial scheme to overbill Medicare. We ... employee of a medical equipment company if their ... medical practice groups with extra generous incentives to use, ...
(Date:5/9/2017)... -- Oramed Pharmaceuticals Inc. (NASDAQ: ORMP ) ... on the development of oral drug delivery systems, ... has granted Oramed a patent titled, "Methods and ... covers Oramed,s invention of an oral glucagon-like peptide-1 ... hormone that stimulates the secretion of insulin from ...
Breaking Medicine Technology: